obesity-995x60.png
FEATURED ARTICLES
Threat From Within: Why Biopharma's Drug Development Bottleneck Is Systemic
As FDA timelines and AI-enabled development accelerate, biopharma’s biggest bottleneck may be its own ability to make earlier, cross-functional decisions.
-
From Signal To Strategy: What Oncology Basket Trials Can Teach Clinical Development Teams
AbbVie's Svetlana Kobina discusses how basket trials can help clinical development teams move from early clinical signals to a more disciplined strategy.
-
What 9 Years Of MDR Experience Is Changing About PMCF Planning
Re-evaluate your compliance roadmap by exploring expert perspectives on navigating regulatory shifts, distinguishing core surveillance obligations, and building a defensible, value-driven clinical data strategy.
-
Inside ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive T-Cell Malignancies
ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for agressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.